Patent ID: 9370560
Filing Date: 2016-06-21
CPC Classification: A61K,A61P,C07K

Claim Text:
1. A method of inducing and maintaining an immune response to HER2/neu expressing tumor cells in a subject who is in clinical remission from a HER2/neu expressing tumor characterized as having a fluorescence in situ hybridization (FISH) rating of less than about 2.0 for HER2/neu gene expression, the method comprising: (a) inducing immunity to HER2/neu expressing tumor cells by administering to the subject a vaccine composition at least 1 time per month for three to six months, the vaccine composition comprising a peptide having the amino acid sequence of SEQ ID NO: 2 or variant thereof, wherein immunity is established by a statistically significant increase in the presence of CD8+ cells specific for the peptide in peripheral blood mononuclear cells of the patient when compared to pre-vaccine levels; and (b) maintaining immunity to HER2/neu expressing tumor cells by administering a vaccine booster composition to the subject about 6 months after the primary immunization schedule is completed, the booster composition comprising a peptide having the amino acid sequence of SEQ ID NO: 2 or variant thereof.